Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Pituitary Disorders
How do you approach mild prolactin elevations (20-80) in women with galactorrhea on nipple stimulation but regular menses and no plans for pregnancy?
Answer from: at Community Practice
I get baseline MRI of the sella and then monitor prolactin every 6-12 months. I don't treat unless the patient develops symptoms.
Comments
at Access Endocrinology Llc
I agree with Dr. @Sharma, rarely large tumors can ...
13080
Sign in or Register to read more
24117
Related Questions
For patients with central hypothyroidism and a clear etiology (such as recent head irradiation), do you recommend brain imaging prior to starting thyroid hormone replacement therapy?
When and how do you taper off cabergoline therapy for treatment of microprolactinoma?
When do you check macroprolactin in the evaluation of hyperprolactinemia?
When do you consider using setmelanotide for treatment of hypothalamic obesity?
Does growth hormone (GH) replacement therapy reduce the risk of fractures in patients with GH deficiency?
How do you approach monitoring for autoimmune disorders in patients with surgical remission of Cushing’s disease, given the higher incidence of autoimmune disease in this population?
Would you consider treating empirically for AVP deficiency in a patient who had pituitary surgery 6 months earlier and complaints of polyuria/polydipsia with dilute urine (without performing water deprivation studies)?
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
Do you interpret failure to develop hypernatremia with prolonged water deprivation (such as for 12 hours) as evidence against diabetes insipidus even if the urine osmolality is just below normal?
Given the new 2022 WHO classification of pituitary tumors, should we be regularly counseling our patients about the risk of malignancy for what we previously referred to as pituitary adenomas but now classified as pituitary neuroendocrine tumors (PitNETs)?
I agree with Dr. @Sharma, rarely large tumors can ...